Prognostic value of nuclear maspin expression for adjuvant 5-fluorouracil-based chemotherapy in advanced gastric cancer

Experimental and Therapeutic Medicine

Volumn 3, Issue 6, 2012, Pages 993-998

  Lei, Ke Feng ^a,b   Liu, Bing Ya ^a   Jin, Xiao Long ^a   Guo, Yan ^a   Ye, Min ^a   Zhu, Zheng Gang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

5 fluorouracil based chemotherapy; Gastric cancer; Immunohisto chemistry; Maspin; Prediction

Indexed keywords

FLUOROURACIL; FOLINIC ACID; MASPIN;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PROGNOSIS; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTINUOUS INFUSION; CYTOPLASM; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN EXPRESSION; STOMACH CANCER; SURVIVAL PREDICTION; TUMOR CELL;

EID: 84859462364     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.532     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
2. Yang L: Incidence and mortality of gastric cancer in China. World J Gastroenterol 12: 17-20, 2006.
3. Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345: 725-730, 2001.
4. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research Collaboration) Group, Paoletti X, Oba K, Burzykowski T, et al: Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 303: 1729-1737, 2010.
5. Zou Z, Anisowicz A, Hendrix MJ, et al: Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 263: 526-529, 1994.
6. Ogasawara S, Maesawa C, Yamamoto M, et al: Disruption of cell-type-specific methylation at the Maspin gene promoter is frequently involved in undifferentiated thyroid cancers. Oncogene 23: 1117-1124, 2004.
7. Umekita Y, Ohi Y, Sagara Y, et al: Expression of maspin predicts poor prognosis in breast-cancer patients. Int J Cancer 100: 452-455, 2002.
8. Ohike N, Maass N, Mundhenke C, et al: Clinicopathological significance and molecular regulation of maspin expression in ductal adenocarcinoma of the pancreas. Cancer Lett 199: 193-200, 2003.
9. Sood AK, Fletcher MS, Gruman LM, et al: The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res 8: 2924-2932, 2002.
10. Kim SM, Cho SJ, Jang WY, et al: Expression of maspin is associated with the intestinal type of gastric adenocarcinoma. Cancer Res Treat 37: 228-232, 2005.
11. Song SY, Son HJ, Kim MH, et al: Prognostic significance of maspin expression in human gastric adenocarcinoma. Hepatogastroenterology 54: 973-976, 2007.
12. Harvey JM, Clark GM, Osborne CK, et al: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474-1481, 1999.
13. Boku N: Perspectives for personalization in chemotherapy of advanced gastric cancer. Discov Med 9: 84-89, 2010.
14. Wagner AD, Grothe W, Haerting J, et al: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24: 2903-2909, 2006.
15. Won HJ, Ha TK, Kwon SJ, et al: Differential effects of 5-fluorouracil on glucose transport and expressions of glucose transporter proteins in gastric cancer cells. Anticancer Drugs 21: 270-276, 2010.
16. Jakobsen A, Nielsen JN, Gyldenkerne N, et al: Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 23: 1365-1369, 2005.
17. Ajani JA: Evolving chemotherapy for advanced gastric cancer. Oncologist 10 (Suppl 3): 49-58, 2005.
18. Park DJ and Lenz HJ: Determinants of chemosensitivity in gastric cancer. Curr Opin Pharmacol 6: 337-344, 2006.
19. Kubota T and Weisenthal L: Chemotherapy sensitivity and resistance testing: to be 'standard' or to be individualized, that is the question. Gastric Cancer 9: 82-87, 2006.
20. Dietmaier W, Bettstetter M, Wild PJ, et al: Nuclear Maspin expression is associated with response to adjuvant 5-fluorouracil based chemotherapy in patients with stage III colon cancer. Int J Cancer 118: 2247-2254, 2006.
21. Zheng Z, Li J, He X, et al: Involvement of RhoGDI2 in the resistance of colon cancer cells to 5-fluorouracil. Hepatogastroenterology 57: 1106-1112, 2010.
22. Sheng S, Truong B, Fredrickson D, et al: Tissue-type plasminogen activator is a target of the tumor suppressor gene maspin. Proc Natl Acad Sci USA 95: 499-504, 1998.
23. Dokras A, Gardner LM, Kirschmann DA, et al: The tumour suppressor gene maspin is differentially regulated in cytotrophoblasts during human placental development. Placenta 23: 274-280, 2002.
24. Shi HY, Zhang W, Liang R, et al: Modeling human breast cancer metastasis in mice: maspin as a paradigm. Histol Histopathol 18: 201-206, 2003.
25. Zhang M, Volpert O, Shi YH, et al: Maspin is an angiogenesis inhibitor. Nat Med 6: 196-199, 2000.
26. Mohsin SK, Zhang M, Clark GM, et al: Maspin expression in invasive breast cancer: association with other prognostic factors. J Pathol 199: 432-435, 2003.
27. Marioni G, Blandamura S, Giacomelli L, et al: Nuclear expression of maspin is associated with a lower recurrence rate and a longer disease-free interval after surgery for squamous cell carcinoma of the larynx. Histopathology 46: 576-582, 2005.
28. Lee DY, Park CS, Kim HS, et al: Maspin and p53 protein expression in gastric adenocarcinoma and its clinical applications. Appl Immunohistochem Mol Morphol 16: 13-18, 2008.
29. Ben Shachar B, Feldstein O, Hacohen D, et al: The tumor suppressor maspin mediates E2F1-induced sensitivity of cancer cells to chemotherapy. Mol Cancer Res 8: 363-372, 2010.